Moderna’s mRESVIA vaccine gains Health Canada approval
The approval by Health Canada is supported by the outcomes from the ConquerRSV Phase III study.
Trilink Thematic mRNA WP
mRNA licensing agreements surge 800% amid GSK lawsuits
Anima Biotech’s machine learning programme ‘reveals new mRNA drug targets’
A rational design approach to RNA targeting could replace large-scale screening
mRNA Covid-19 vaccines may boost cancer immunotherapy effectiveness
Japan approves updated Covid-19 vaccine to tackle JN.1 variant
Moderna’s Laval facility gains Health Canada’s drug establishment licence
ESC 2024: Insights into RNA as therapeutic target and tool
